Ventripoint Diagnostics Seeks TSXV Approval for Private Placement Extension and Increase

Toronto, Ontario — October 3, 2025 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV:VPT) is seeking approval from the TSX Venture Exchange (TSXV) to extend its previously announced non-brokered private placement of unsecured convertible debentures to November 2, 2025.

The company also seeks approval from the TSXV to increase the size of the offering from $500,000 to $560,000.

Each unit comprises one unsecured convertible debenture with a principal amount of $1,000, convertible into common shares of the corporation, and 9,000 common share purchase warrants.

The debentures are convertible into common shares of the corporation at the holder's option at any time before maturity at a conversion price of $0.11 per common share. Each whole warrant entitles the holder to purchase one common share at a price of $0.14 until December 31, 2027.

The debentures mature on December 31, 2027, and bear interest at 10% payable semi-annually in arrears in either cash or, at the corporation's option, by issuing common shares at a 20-day VWAP market price, subject to exchange approval.

Ventripoint will use the offering proceeds to fund operational costs related to sales and marketing, additional key personnel, and general working capital purposes.

All securities issued are subject to a hold period of four months plus one day from the offering's closing date and are subject to final approval by the Exchange.

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Source: Ventripoint Diagnostics Ltd.